Ignite Creation Date:
2024-05-06 @ 2:57 PM
Last Modification Date:
2024-10-26 @ 1:40 PM
Study NCT ID:
NCT04475601
Status:
TERMINATED
Last Update Posted:
2022-06-02
First Post:
2020-06-08
Brief Title:
Enzalutamide Treatment in COVID-19
Sponsor:
Andreas Josefsson
Organization:
Region Västerbotten
Study Overview
Official Title:
A Prospective Multicenter Randomized PHASE II Clinical Trial of Enzalutamide Treatment to Decrease the Morbidity in Patients With Corona Virus Disease 2019 COVID-19
Status:
TERMINATED
Status Verified Date:
2021-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
By sponsor based on DSMB recommendations
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
COVIDENZA
Brief Summary:
COVID-19 is a disease with high rate of morbidity if symptomatic There is a great need of treatments to decrease the severity The vast majority of patients needing intensive care are men and this may be due to the androgens either by regulation of TMPRSS2 necessary for virus internalization or other mechanisms Enzalutamide is an antiandrogen inhibiting the expression of androgen regulated proteins such as TMPRSS2 The aim of this trial is to evaluate a possible beneficial effect of short-term enzalutamide treatment of COVID-19 patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None